Last edition
News about "CARsgen Advances Allogeneic"
CARsgen Advances Allogeneic CAR-T Manufacturing with Dual IND Filings
CARsgen Therapeutics Holdings Limited announced that it has submitted two separate Investigational New Drug (IND) applications to China’s National Medical Products Administration for its allogeneic BCMA-targeted CAR T-cell therapy, CT0596.
CARsgen Advances Allogeneic | 30/12/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members